AutoCRAT is developing rational and sustainable cell and cell-based/guided therapies for osteoarthritis (OA) with the concurrent development of closed, scalable and regulatory-compliant automated systems for aseptic therapeutic moieties (whether cell or cell-based manufacturing) for the delivery of therapeutics to patients.

The project addresses the following therapeutic challenges:
1) to identify optimal, next-generation therapies for OA and cartilage repair whether cell-mediated or cell-guided,
2) the economic, sustainable, regulatory-compliant production of
a) allogeneic donor-derived MSC,
b) sustainable and reproducible human induced pluripotent stem cells (iPSC)-derived MSC and human iPSC-derived articular chondrocytes and
c) their secreted therapeutic cargo, and
3) to progress the translation and delivery of the therapies by complying with regulatory requirements and creating a sustainable commercialisation pathway to ensure that patients benefit.

AutoCRAT delivers novel therapies at scale by addressing cost-effective, automated production of developed therapeutic entities to deliver consistent clinical products with minimised contamination, maximised scale and reduced cost of goods. The project outputs are designed with regulatory compliance and effective, affordable delivery to a large number of patients as underpinning elements. The technologies developed to produce human therapeutic cells or secreted factors extend beyond OA and address many diseases that can be treated by MSC.

AutoCRAT has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874671. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.

Date: 1 January 2020 - 31 December 2023